pe-22-28 dosage FAQ

Assume partial degradation and plan accordingly. Peptides are more stable than most researchers expect—a single 12–16 hour room temperature exposure won't turn your solution into saline—but it will reduce potency by an unknown percentage, typically 10–30% depending on ambient temperature and light exposure. If the experiment is low-stakes (e.g., preliminary dose-response testing), you can proceed with the caveat that your effective dose may be lower than calculated. If the experiment is high-stakes (e.g., final data collection for a manuscript), discard the vial and reconstitute fresh peptide. The cost of one 5mg vial is negligible compared to the cost of repeating weeks of animal work because your dosing was inconsistent. One mitigation: if you catch the oversight early (within 2–4 hours), refrigerate the vial immediately and use it within 7 days rather than the standard 28—condensed timeline reduces cumulative degradation. Temperature excursions are cumulative. One overnight mistake plus two weeks of proper refrigeration is better than one overnight mistake plus three more weeks of refrigeration, during which additional slow degradation occurs.

Discard it immediately. Visible particulates indicate peptide aggregation, contamination, or both—none of which can be reversed. Aggregated peptides lose binding affinity for TREK-1 receptors, rendering the solution ineffective regardless of the original concentration. Filtration through a 0.22µm syringe filter removes particulates but does not restore peptide structure or potency. Cloudiness that appears within hours of reconstitution suggests contamination during the reconstitution process (non-sterile water, unclean vial, or airborne particulates introduced when the seal was broken). Cloudiness that develops over days to weeks in a refrigerated vial indicates peptide degradation—possibly from repeated temperature fluctuations if the vial was removed from refrigeration multiple times or from light exposure if stored without light protection. In both cases, the peptide content has chemically changed in ways that HPLC or mass spec could quantify but that you cannot reverse in the lab. Starting with a fresh vial costs less than running an entire experiment with degraded peptide and getting null results you can't interpret.

Split your daily dose into two administrations 8–12 hours apart, maintaining the same total daily milligram amount. PE-22-28's half-life in rodent plasma is approximately 2–4 hours (based on pharmacokinetic studies of structurally similar peptides), meaning a single morning injection results in near-complete clearance by evening. If your experimental question examines sustained TREK-1 blockade—such as chronic stress resilience or continuous neurogenesis promotion—twice-daily dosing maintains more consistent receptor occupancy than once-daily. Practically, this means a 0.5mg/kg total daily dose becomes 0.25mg/kg every 12 hours. Injection volume remains low (most protocols use 50–100µL per injection), minimizing tissue irritation from repeated subcutaneous administration at the same site. Rotate injection sites (scruff, flank, lower back) to prevent localized inflammation that can alter peptide absorption. Twice-daily dosing doubles your peptide consumption and labor time, so reserve it for protocols where sustained receptor blockade is mechanistically necessary—most published PE-22-28 studies use once-daily dosing and still observe robust neuroplasticity effects.

Check three variables before assuming the peptide failed: actual delivered dose, peptide purity, and experimental model alignment. Actual delivered dose is the most common culprit. If you reconstituted a 5mg vial with 2mL water intending 2.5mg/mL but later discovered the vial contained only 4mg peptide (confirmed by CoA), your actual concentration was 2mg/mL—a 20% error that shifts your entire dose-response curve. Always verify vial content via CoA before calculating reconstitution volumes. Peptide purity matters more for some endpoints than others. A 95% pure PE-22-28 sample performs identically to 98% pure in most behavioral assays, but in patch-clamp electrophysiology measuring TREK-1 current, that 3% impurity—if it includes structurally similar truncated peptides—can produce confusing off-target effects. Request HPLC traces and mass spec data from your supplier; Real Peptides includes both with every batch. Experimental model alignment is the subtlest failure point. If published data used 8–10 week old male C57BL/6 mice and you're using 16-week-old female CD-1 mice, baseline TREK-1 expression, hippocampal neurogenesis rates, and stress reactivity differ enough to alter dose-response. Strain, sex, and age aren't minor details—they're biological variables that change receptor density and peptide metabolism.

If a dose is missed by less than 2 hours, administer as soon as remembered and continue the regular schedule. For missed doses beyond 2 hours, skip the missed dose and resume normal timing for the next scheduled administration.[2] Never double dose to compensate for missed administrations, as this can increase side effect risk and disrupt steady-state pharmacokinetics.

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.

Switch from daily to every-other-day dosing at the same 1 mg/kg dose. While TREK-1 doesn't downregulate like opioid receptors, chronic peptide administration can trigger compensatory changes in downstream signaling pathways (PKA, ERK) that blunt behavioral effects. Alternatively, pulse dosing (3 days on, 2 days off) maintains TREK-1 modulation while preventing adaptive responses. Monitor body weight daily. Pe-22-28 doesn't affect appetite directly, but injection stress from daily handling can suppress feeding in some animals.

Verify peptide integrity first. Run HPLC or mass spec on the reconstituted solution to confirm the compound hasn't degraded. If storage was compromised (temperature excursion, repeated freeze-thaw cycles), the peptide may have lost TREK-1 binding activity despite appearing clear in solution. Second, confirm injection technique: subcutaneous delivery into adipose tissue produces slower, more variable absorption than subcutaneous injection into the scruff with proper needle depth. Third, consider baseline neurochemical state. Subjects with severely depleted hippocampal BDNF (e.g., chronic unpredictable stress models lasting >6 weeks) may require 21–28 days for remodelling to translate into behavioural change.

You won't get meaningfully better results than 5mg/kg. MC4R occupancy plateaus around 70–78%, so tripling the dose from 5mg/kg to 15mg/kg increases receptor engagement by less than 10% while raising off-target MC3R binding threefold. The Moscow State study found that BDNF upregulation at 15mg/kg was statistically indistinguishable from 10mg/kg, and some animals showed reduced hippocampal neurogenesis markers at 20mg/kg. Likely due to negative feedback on the HPA axis. Higher doses also increase peptide waste and cost without improving outcomes.

The peptide is likely degraded. PE-22-28 is a synthetic fragment of ACTH with a primary structure vulnerable to enzymatic cleavage and oxidation at ambient temperature. Studies show that lyophilized peptides maintain stability at room temperature for 24–48 hours, but once reconstituted with bacteriostatic water, enzymatic degradation accelerates rapidly above 4°C. A vial left at 20–25°C overnight may retain 40–60% of initial potency. Not enough to produce therapeutic BDNF upregulation. Discard it and reconstitute a fresh vial. Storage failures are the single most common reason for 'non-responder' outcomes in peptide research protocols.

No. PE-22-28's mechanism depends on sustained CREB phosphorylation, not peak plasma levels. Missing a dose creates a transient dip in neurogenic signaling, but doubling the next dose doesn't compensate. It just oversaturates receptors that are already near maximal occupancy. If you miss a dose by fewer than 12 hours, administer it as soon as remembered and continue the regular schedule. If more than 12 hours have passed, skip the missed dose and resume normally. Doubling doses raises the risk of appetite suppression and cortisol disruption.

PE-22-28 doesn't induce withdrawal or rebound hyperactivity of TREK-1 channels, so brief interruptions are tolerated better than SSRI discontinuation. However, plasma levels drop to negligible within 24 hours, and cumulative BDNF upregulation may plateau or slightly decline during the gap. If interruption is unavoidable, resume at the same dose. Do not double-dose to 'catch up.' Our team has observed that a single 48-hour gap in a 21-day protocol delays behavioural efficacy by approximately 3–5 days but does not eliminate the effect entirely.

Increase to 2 mg/kg and verify reconstitution pH was 7.2–7.4. The most common cause of null results isn't underdosing. It's peptide aggregation during reconstitution or storage at incorrect temperature. If 2 mg/kg still produces no detectable effect, run a Western blot for TREK-1 surface expression in hippocampal tissue at 60 minutes post-injection. This confirms whether the peptide reached target tissue. Some rodent strains (particularly outbred CD-1 mice) show 30–40% lower baseline TREK-1 expression than C57BL/6, requiring higher doses or longer pre-treatment windows.

Start with the lowest effective dose identified in animal models: 0.08mg/kg (approximately 5.6mg for a 70kg individual) administered subcutaneously. Monitor for subjective effects over 60–90 minutes. The mechanism involves receptor upregulation rather than immediate binding, so onset is slower than benzodiazepines. If no response occurs after three doses administered on separate days, incremental increases of 2–3mg could be considered, though this exceeds published human data and carries unknown risk.

Confirm DMSO concentration is below 0.1% and that culture medium pH is 7.3–7.5. Pe-22-28 activity drops sharply in acidic conditions. Increase concentration to 25 µM or 50 µM. Some neuronal preparations with high endogenous sortilin expression require higher peptide concentrations to saturate the TREK-1 binding sites. If no response at 50 µM, verify TREK-1 channel expression in your cell line via qPCR or immunocytochemistry. Not all neuronal lines express functional TREK-1 channels at detectable levels.

Yes, maintain 0.5 mg/kg daily even in short pilot studies. Dose reduction extends the lag before observable BDNF elevation. Early-stage protocols testing proof-of-concept should use the established efficacious dose to maximise signal detection. TREK-1 blockade is measurable within 24 hours, but behavioural phenotypes require 7–10 days minimum. If your endpoint is molecular (BDNF protein quantification, synaptic marker expression), 7 days at 0.5 mg/kg produces detectable effects. If your endpoint is behavioural (forced swim test, sucrose preference), extend to 14 days minimum.

No interaction studies exist for PE-22-28 with any pharmaceutical agent. Theoretical concerns include additive GABAergic effects if combined with benzodiazepines (though the mechanisms differ. PE-22-28 doesn't bind the benzodiazepine site directly) or serotonergic modulation overlap with SSRIs (though published data doesn't show serotonin pathway involvement). The conservative approach: discontinue other anxiolytics before introducing PE-22-28 in a research context, or consult a research physician familiar with peptide pharmacology before combining agents.

Absence of subjective effect doesn't necessarily mean absence of receptor modulation. The mechanism is subunit expression changes that may not produce immediate conscious awareness. Objective measures (heart rate variability, cortisol response to stressors, behavioural tasks under controlled conditions) might detect changes that subjective reporting misses. Alternatively, individual variation in peptidase activity or blood-brain barrier permeability could reduce bioavailability below the threshold needed for GABAergic modulation. No published data exists on non-responder rates or predictive biomarkers.

Calculate the new injection volume using your existing concentration: 300mcg ÷ 2,500mcg/mL = 0.12mL, which equals 12 units on a U-100 insulin syringe. You don't need to re-reconstitute the vial. Just adjust the syringe volume you draw. Write '12 units = 300mcg' on the vial label to avoid recalculating each dose. If your protocol changes mid-cycle, the concentration stays constant. Only the drawn volume changes.

Some volume loss during transfer is normal due to needle dead space and vial surface tension. Use the actual volume you added. 1.8mL. For your concentration calculation, not the intended 2mL. A 5mg vial with 1.8mL yields 5mg ÷ 1.8mL = 2.78mg/mL (2,778mcg/mL). For a 250mcg dose: 250 ÷ 2,778 = 0.09mL or 9 units. Precision matters. Assuming 2mL when you actually added 1.8mL creates a 10% dosing error across the entire vial.